People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotechnology, Other Health Care, Medical Devices, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tissuetech, Inc. | — | Biotechnology | Series C | $83.0M | $2.3B | 2013 |
| Urgent Team Holdings, Inc. | — | Other Health Care | Series B | $61.5M | $163.5M | 2012 |
| NICO Corp | — | Other Health Care | Series B | $58.7M | $143.0M | 2022 |
| Spineology Inc | — | Biotechnology | Series B | $55.9M | $35.0M | 2023 |
| Checkpoint Surgical, Inc. | — | Medical Devices | Series A | $35.2M | $20.8M | 2024 |
| Catalyst OrthoScience Inc | — | Other | Series B | $24.6M | $19.6M | 2023 |
| Orthohelix Surgical Design Inc | — | Other Health Care | Series A | $23.4M | $283.2M | 2008 |
| Bolder Surgical Holdings, Inc. | — | Medical Devices | Series B | $18.2M | $5.1M | 2018 |
| Health Integrated Inc | — | Other Health Care | Seed | $7.2M | $74.4M | 2010 |
| Orthoscan Inc | — | Other Health Care | Pre-Seed | $825K | $25.4M | 2010 |
Carter McNabb at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carter McNabb on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wayne Wallace | 3 | 4 |
| Ned Scheetz | 1 | 8 |
| David Fitzgerald | 1 | 7 |
| David Kay | 1 | 6 |
| David Friend | 1 | 6 |
| Leonard M. Cosentino | 1 | 5 |
| Michael Chuisano | 1 | 5 |
| Derek Lewis | 1 | 5 |
| Steven Goldberg | 1 | 5 |
| Matt Rice | 1 | 5 |
| Thomas Flynn | 1 | 4 |
| James Tyler | 1 | 4 |
| ROBERT KAUFMAN | 1 | 4 |
| STEVE WIGGINTON | 1 | 4 |
| David L Wood | 1 | 4 |
| J. ROBERT PAULSON | 1 | 4 |
| John Booth | 1 | 4 |
| Greg Collins | 1 | 4 |
| Geoffrey Thrope | 1 | 4 |
| Derace L Schaffer | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.